1-[4-(2,2,2-trifluoroethoxy)phenyl]ethylamine | 942938-39-8

• 英文名称: 1-[4-(2,2,2-trifluoroethoxy)phenyl]ethylamine
• 英文别名: 1-[4-(2,2,2-trifluoroethoxy)phenyl]ethanamine；1-[4-(2,2,2-Trifluoroethoxy)phenyl]ethan-1-amine
• CAS: 942938-39-8
• 化学式: C₁₀H₁₂F₃NO
• 分子量: 219.207
• InChiKey: ZARTWYNUPAMSJI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-[4-(2,2,2-trifluoroethoxy)phenyl]ethylamine 、 3-oxo-2-(2-pyridin-2-ylethyl)-1H-isoindole-1-carboxylic acid 在 三乙胺 、 fluoro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.08h， 以13%的产率得到3-oxo-2-(2-pyridin-2-ylethyl)-N-[1-[4-(2,2,2-trifluoroethoxy)phenyl]ethyl]-1H-isoindole-1-carboxamide
  参考文献：
  名称：

  3-Oxoisoindoline-1-carboxamides: Potent, State-Dependent Blockers of Voltage-Gated Sodium Channel Na_V1.7 with Efficacy in Rat Pain Models

  摘要：

  The voltage-gated sodium channel Na(V)1.7 is believed to be a critical mediator of pain sensation based on clinical genetic studies and pharmacological results. Clinical utility of nonselective sodium channel blockers is limited due to serious adverse drug effects. Here, we present the optimization, structure activity relationships, and in vitro and in vivo characterization of a novel series of Na(V)1.7 inhibitors based on the oxoisoindoline core. Extensive studies with focus on optimization of Na(V)1.7 potency, selectivity over Na(V)1.5, and metabolic stability properties produced several interesting oxoisoindoline carboxamides (16A, 26B, 28, 51, 60, and 62) that were further characterized. The oxoisoindoline carboxamides interacted with the local anesthetics binding site. In spite of this, several compounds showed functional selectivity versus Na(V)1.5 of more than 100-fold. This appeared to be a combination of subtype and state-dependent selectivity. Compound 28 showed concentration-dependent inhibition of nerve injury-induced ectopic in an ex vivo DRG preparation from SNL rats. Compounds 16A and 26B demonstrated concentration-dependent efficacy in preclinical behavioral pain models. The oxoisoindoline carboxamides series described here may be valuable for further investigations for pain therapeutics.

  DOI：

  10.1021/jm300623u
• 作为产物：
  描述：

  3-Pyridinemethanamine, alpha-methyl-6-(2,2,2-trifluoroethoxy)- 、 4-(2,2,2-三氟乙氧基)苯甲腈 生成 1-[4-(2,2,2-trifluoroethoxy)phenyl]ethylamine
  参考文献：
  名称：

  New Compounds

  摘要：

  本发明涉及新化合物或其盐、溶剂合物或溶剂盐，其制备方法以及用于制备它们的新中间体，含有这些化合物的制药组合物以及将这些化合物用于治疗的用途。

  公开号：

  US20100286202A1

文献信息

• [EN] ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS D'ARYLAMIDE EN TANT QU'AGENTS BLOQUANTS DE TTX-S
  申请人：RAQUALIA PHARMA INC

  公开号：WO2012053186A1

  公开（公告）日：2012-04-26

  The present invention relates to arylamide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及具有对电压门控钠通道（如TTX-S通道）具有阻塞活性的芳基酰胺衍生物，用于治疗或预防涉及电压门控钠通道的疾病和疾病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及电压门控钠通道的这类疾病中使用这些化合物和组合物。
• Compounds
  申请人：Besidski Yevgeni

  公开号：US20080171770A1

  公开（公告）日：2008-07-17

  The present invention relates to new compounds or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.

  本发明涉及新化合物或其盐、溶剂合物或溶剂盐，以及制备它们的过程，用于制备中间体的新方法，含有该化合物的制药组合物以及在治疗中使用该化合物的用途。
• ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS
  申请人：Yamagishi Tatsuya

  公开号：US20140336377A1

  公开（公告）日：2014-11-13

  The present invention relates to arylamide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及一种芳基酰胺衍生物，其具有阻断电压门控钠通道（如TTX-S通道）的活性，并且在涉及电压门控钠通道的疾病和疾病的治疗或预防中有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在涉及电压门控钠通道的这种疾病的预防或治疗中的使用。
• [EN] GPR84 ANTAGONISTS AND USES THEREOF<br/>[FR] ANTAGONISTES DU GPR84 ET LEURS UTILISATIONS
  申请人：LIMINAL BIOSCIENCES LTD

  公开号：WO2022167445A1

  公开（公告）日：2022-08-11

  The present invention provides compounds of formula I, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.

  本发明提供了I式化合物，其组成物和使用相应物质抑制GPR84以及治疗GPR84介导的疾病的方法。
• NEW COMPOUNDS III
  申请人：AstraZeneca AB

  公开号：EP1966156A2

  公开（公告）日：2008-09-10